Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRX-102 vs agalsidase beta in Fabry disease with impaired renal function
2016-000378-38Phase 3Unknown
- Sponsor
- Protalix BioTherapeutics
- Start
- Jul 2016
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, PEGylated Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pegunigalsidase alfa in Fabry disease (FD) (2 arms), sponsored by Protalix BioTherapeutics. Primary endpoint: Annualized change in eGFR (CKD-EPI). Status: unknown.
02
Drugs
pegunigalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2016-000378-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000378-38.